Positive (ER+) patients, 5 years of adjuvant tamoxifen (that suppresses ER) reduces breast cancer mortality by approximately one third (0-14 years), recurrence about half (0-4 years) and about one third (5-9 years) (33). The gene discussed is ESR1; the disease is breast cancer.